Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05305859 | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | not yet recruiting | Phase 2 / Phase 3 | 306 | Actinium PharmaceuticalsINDUSTRY | 0 | Sep 10, 2025 | clinicaltrials |
| NCT04150497 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | recruiting | Phase 1 / Phase 2 | 52 | Cellectis S.A.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07022743 | Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy | active not recruiting | Phase 2 | 75 | Obafemi Awolowo UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06382168 | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 39 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT04501939 | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax(Venetoclax) | active not recruiting | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT06855810 | Newly-diagnosed Pediatric T-cell ALL Protocol(CCCG-TALL-2025) | recruiting | Phase 2 / Phase 3 | 610 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol(CCCG-LR-B-ALL) | recruiting | Phase 2 / Phase 3 | 3,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT04023526 | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy(CULMINATE) | active not recruiting | Phase 2 | 103 | OncoVerity, Inc.INDUSTRY | 9 | Aug 20, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
| NCT06978088 | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | recruiting | Phase 2 | 34 | Zulfa OmerOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05667506 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | recruiting | Phase 1 / Phase 2 | 47 | Juventas Cell Therapy Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06530550 | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 51 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04099966 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | recruiting | Phase 2 | 20 | Mitchell CairoOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07023588 | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease | recruiting | Phase 2 | 70 | Yehui TanOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07108530 | Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study | recruiting | Phase 2 | 50 | Shanxi Bethune HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07109323 | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04440267 | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06930105 | Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL | not yet recruiting | Phase 2 | 45 | Xianmin Song, MDOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07105579 | Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 31 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05979363 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia(CAREMM-002) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101497 | Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05660473 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06058572 | Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia | recruiting | Phase 2 | 166 | Tata Memorial CentreOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | recruiting | Phase 2 | 50 | Beijing 302 HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06984536 | Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT | recruiting | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07072494 | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study | recruiting | Phase 1 / Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07069933 | Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options? | not yet recruiting | Phase 2 | 50 | Mansoura UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07059156 | Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL | recruiting | Phase 2 / Phase 3 | 50 | Shanxi Bethune HospitalOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML(PEARL) | recruiting | Phase 2 | 160 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT04851717 | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | active not recruiting | Phase 2 / Phase 3 | 100 | Acacia Pharma LtdINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT01985061 | Evaluation of 3 Different Doses of IV Busulfan(AAA) | active not recruiting | Phase 2 | 177 | Institut Paoli-CalmettesOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"(DARA_T_ALL) | recruiting | Phase 2 | 18 | Tata Memorial CentreOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT06862323 | Time Restricted Eating in Haematological Malignancies | not yet recruiting | Phase 2 | 75 | British Columbia Cancer AgencyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies(PACMAN) | not yet recruiting | Phase 1 / Phase 2 | 18 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04687176 | Frontline Oral Arsenic Trioxide for APL | recruiting | Phase 2 | 100 | The University of Hong KongOTHER | 2 | Jun 12, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Sep 11, 2025source: clinicaltrials